Molecular structure of Cadralazine, CAS Number: 64241-34-5
Cadralazine (CAS 64241-34-5)
Application:
Cadralazine is a peripheral arteriolar vasodilator
CAS Number:
64241-34-5
Molecular Weight:
283.33
Molecular Formula:
C12H21N5O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Cadralazine is a chemical compound that functions as a vasodilator in experimental applications. It acts by targeting and relaxing the smooth muscle cells in blood vessels, leading to the widening of the vessels and subsequently lowering blood pressure. Cadralazine achieves its mechanism of action by inhibiting the influx of calcium ions into the smooth muscle cells. By blocking this influx, Cadralazine effectively promotes vasodilation and reduces peripheral resistance, ultimately contributing to its functional role as a vasodilator. This mechanism of action at the molecular level allows for the experimental exploration of its potential effects on blood pressure regulation and vascular function.
Cadralazine (CAS 64241-34-5) References
- Pharmacokinetics of cadralazine and its hydrazino-metabolite in patients with renal impairment after repeated administration of 5 mg once daily. | Marichal, JF., et al. 1992. Eur J Drug Metab Pharmacokinet. 17: 213-20. PMID: 1490491
- Cadralazine for the treatment of preeclampsia. An open, noncomparative, dose-finding pilot study. | Voto, LS., et al. 1992. Hypertension. 19: II132-6. PMID: 1735567
- Cadralazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. | McTavish, D., et al. 1990. Drugs. 40: 543-60. PMID: 2083513
- Cadralazine, a new vasodilator, in addition to a beta-blocker for long-term treatment of hypertension. | Salvadeo, A., et al. 1985. Arzneimittelforschung. 35: 623-5. PMID: 2859865
- Pharmacokinetics of cadralazine in hypertensive patients. | Leonetti, G., et al. 1988. Eur J Drug Metab Pharmacokinet. 13: 295-300. PMID: 3243325
- Antihypertensive activity of cadralazine in experimental hypertensive rats. | Takeyama, K., et al. 1988. Arch Int Pharmacodyn Ther. 291: 163-74. PMID: 3365060
- Hemodynamic effects of cadralazine in hexamethonium treated and non-treated anesthetized dogs. | Higashio, T., et al. 1988. Arzneimittelforschung. 38: 350-8. PMID: 3382459
- [Effects of cadralazine on the central nervous system]. | Nishimori, T., et al. 1988. Nihon Yakurigaku Zasshi. 91: 209-20. PMID: 3391445
- [Effects of cadralazine on the respiration, circulation, kidney, autonomic nervous system, digestive system, blood and so on]. | Nishimori, T., et al. 1988. Nihon Yakurigaku Zasshi. 91: 221-36. PMID: 3391446
- Cadralazine did not produce the SLE-syndrome when hydralazine did. | Andersson, OK. 1987. Eur J Clin Pharmacol. 31: 741. PMID: 3556384
- Disposition and pharmacokinetics of cadralazine and individual metabolites in man. | Schütz, H., et al. 1985. Eur J Drug Metab Pharmacokinet. 10: 147-53. PMID: 4043143
- Pharmacological studies on cadralazine: a new antihypertensive vasodilator drug. | Semeraro, C., et al. 1981. J Cardiovasc Pharmacol. 3: 455-67. PMID: 6168827
- Hemodynamic profile of the antihypertensive vasodilator cadralazine in conscious dogs. | Dorigotti, L., et al. 1984. Arzneimittelforschung. 34: 984-7. PMID: 6542375
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cadralazine, 10 mg | sc-500641 | 10 mg | $52.00 | |||
Cadralazine, 100 mg | sc-500641A | 100 mg | $260.00 |